Sponsor Dossier
Southern XP IP
Sponsor Dossier for Southern XP IP. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: AMIKACIN
- Brand: AMPHOTERICIN LIPOSOMAL
- Brand: ATORVASTATIN-DRLA
- Brand: ATORVASTATIN-RZ
- Brand: AZACITIDINE
- Brand: BETAHISTINE
- Brand: BIVALIRUDIN
- Brand: CAMBIA
About
Southern XP IP is an Australian Private Company with ABN 55639505570, registered in Victoria. The entity status is Active.
Portfolio
Southern XP IP has 33 brands on the ARTG, of which 23 are indexable. The company holds Product Information on file for 20 brands. One brand in the portfolio is PBS-listed. Six brands have AusPARs on record.
Therapeutic focus —
Neurology: 10 brands — Cardiology: 6 brands — Infectious Disease: 4 brands — Gastroenterology: 4 brands — Oncology: 2 brands — Women's Health: 1 brand — Immunology: 1 brand — Urology: 1 brand — Ophthalmology: 1 brand — Pain & Anaesthesia: 1 brand — Dermatology: 1 brand — Other: 1 brand
PBS footprint
One brand in the Southern XP IP portfolio is PBS-listed, with the latest PBS schedule date being 1 May 2026.
Regulatory activity
The most recent AusPAR for Southern XP IP is dated 4 December 2019.